A Phase 1 interventional study of Opevesostat and Prednisone in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-25.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer.
The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to opevesostat in the body when it is given with and without another medicine called carbamazepine.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
History or presence of any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On Day 1 a single dose of opevesostat will be administered under fasting conditions and a single dose of hormone replacement therapy (HRT) (prednisone and fludrocortisone) will be administered under fed conditions approximately 4.5 hours after opevesostat dosing.
Drug: Opevesostat · Drug: Prednisone · Drug: Fludrocortisone acetate
There will be a washout of at least 5 days between opevesostat dosing in Period 1 and the first carbamazepine dosing in Period 2. In Period 2, carbamazepine will be administered twice daily (BID) for 17 consecutive days with a single dose of opevesostat coadministered on the morning of Day 14 under fasting conditions. HRT (prednisone and fludrocortisone) will be administered under fed conditions on Day 14, approximately 4.5 hours after opevesostat and/or carbamazepine dosing.
Drug: Opevesostat · Drug: Prednisone · Drug: Fludrocortisone acetate · Drug: Carbamazepine
Administered via oral tablet per dosing regimen.
Also known as: MK-5684, ODM-208
Administered at a dose of 5 mg or 10 mg dependent on HRT dosing regimen via oral tablets.
Also known as: RAYOS®, STERAPRED®, DELTASONE®
Administered at a dose of 0.05 mg or 0.1 mg dependent on HRT dosing regimen via oral tablets.
Also known as: FLORINEF®
Administered at a dose of 100 mg, 200 mg, or 300 mg BID dependent on dosing regimen via oral capsule (extended-release).
Also known as: TEGRETOL®
Area under the concentration versus time curve from 0 to infinity after single dosing (AUC0-inf) of opevesostat in plasma
AUC0-inf of opevesostat in plasma will be determined.
Time frame: Predose, and at designated timepoints up to 96 hours post-dose
Area under the concentration versus time curve from 0 to last quantifiable sample (AUC0-last) of opevesostat in plasma
AUC0-last of opevesostat in plasma will be determined.
Time frame: Predose, and at designated timepoints up to 96 hours post-dose
Area under the concentration versus time curve from 0 to hour 24 (AUC0-24) of opevesostat in plasma
AUC0-24 of opevesostat in plasma will be determined.
Time frame: Predose, and at designated timepoints up to 24 hours post-dose
Maximum concentration (Cmax) of opevesostat in plasma
Cmax of opevesostat in plasma will be determined.
Time frame: Predose, and at designated timepoints up to 96 hours post-dose
Time to Maximum concentration (Tmax) of opevesostat in plasma
Tmax of opevesostat in plasma will be determined.
Time frame: Predose, and at designated timepoints up to 96 hours post-dose
Apparent terminal half-life (t1/2) of opevesostat in plasma
t1/2 of opevesostat in plasma will be determined.
Time frame: Predose, and at designated timepoints up to 96 hours post-dose
Apparent Clearance (CL/F) of opevesostat in plasma
CL/F of opevesostat in plasma will be determined.
Time frame: Predose, and at designated timepoints up to 96 hours post-dose
Apparent volume of distribution during terminal phase (Vz/F) of opevesostat in plasma
Vz/F of opevesostat in plasma will be determined.
Time frame: Predose, and at designated timepoints up to 96 hours post-dose
Number of participants who experience one or more adverse events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be determined.
Time frame: Up to approximately 49 days
Number of participants who discontinue study intervention due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue from the study due to an AE will be determined.
Time frame: Up to approximately 49 days
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Dec 2024 to primary completion in Feb 2025, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Opevesostat